Macipah 10 mg Tablet Uses, Dosage, Side Effects and more
Macipah 10 mg Tablet was approved in October 2013. It is indicated for patients with pulmonary arterial hypertension, and is marketed under the brand name Opsumit. Macipah 10 mg Tablet is an antagonist/blocker of endothelin receptors on blood vessels and smooth muscle, and, thus, blocks the stimulation of vasculature hypertrophy, inflammation, fibrosis, proliferation, and vasoconstriction. Similar to all drugs acting on the renin-angiotensin system, macitentan is associated with embryo and fetal toxicity, so it should not be used in pregnancy and has special precautions that must be followed for all females of child-bearing age.
Macipah 10 mg Tablet blocks simulators of hypertrophy, inflammation, fibrosis, proliferation, and vasoconstriction.
| Attribute | Details |
|---|---|
| Trade Name | Macipah 10 mg Tablet |
| Availability | Prescription only |
| Generic | Macitentan |
| Macitentan Other Names | Macitentán, Macitentan, Macitentanum |
| Related Drugs | sildenafil, tadalafil, Revatio, Adempas, Opsumit, ambrisentan |
| Weight | 10 mg |
| Type | Tablet |
| Formula | C19H20Br2N6O4S |
| Weight | Average: 588.273 Monoisotopic: 585.963349142 |
| Protein binding | Macitentan is >99% bound to plasma proteins, which are mainly albumin |
| Groups | Approved |
| Therapeutic Class | |
| Manufacturer | UniMed UniHealth Pharmaceuticals Ltd. |
| Available Country | Bangladesh |
| Last Updated: | January 7, 2025 at 1:49 am |
Uses
Macipah 10 mg Tablet is an endothelin receptor antagonist used to manage pulmonary arterial hypertension to delay disease progression.
Macipah 10 mg Tablet is indicated for patients with pulmonary arterial hypertension.
Macipah 10 mg Tablet is also used to associated treatment for these conditions: Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)
How Macipah 10 mg Tablet works
Macipah 10 mg Tablet is an antagonist/blocker of endothelin receptors. Endothelin receptors are found in the endothelial cells of blood vessels and smooth muscle. Macipah 10 mg Tablet binds to the receptors, endothelin A and B (ETA and ETB), which prevents the agonist endothelin -1 (ET-1) from binding and stimulating the ETA and ETB receptors.
See simplified version Macipah 10 mg Tablet also Macipah 10 mg Tablet in banglaToxicity
Macipah 10 mg Tablet has a black box warning of embryo-fetal toxicity. Special precautions must be taken for all females of child-bearing age, and women who are pregnant must not be given macitentan.
Food Interaction
- Take with or without food.
Drug Interaction
Moderate: diltiazemUnknown: charcoal, tadalafil, fluticasone / salmeterol, diphenhydramine, fluticasone / vilanterol, rosuvastatin, glucose, ferrous sulfate, clonazepam, furosemide, levothyroxine, metoprolol, metoprolol, acetaminophen, selexipag, liraglutide, cyanocobalamin, cholecalciferol, sertraline
Disease Interaction
Major: hepatotoxicity/liver impairmentModerate: anemia, fluid retention
Volume of Distribution
Macipah 10 mg Tablet has a volume of distribution of 50L.
Elimination Route
Macipah 10 mg Tablet is administered orally, and it take about 8 hours for maximum plasma concentrations to be reached.
Half Life
The half life of macitentan is 16 hours, and the half life of it's active metabolite is 48 hours.
Clearance
Clearance data was not found.
Elimination Route
Eliminated 50% through urine and 24% through feces.
